Phase II Trial of Ibrutinib and PD-1 Blockade in High Risk Chronic Lymphocytic Leukemia to Improve Immune Dysfunction
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 05 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 25 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
- 04 May 2018 New trial record